NCT06302426 2026-01-16
Trial of INI-4001 in Patients With Advanced Solid Tumours
Inimmune Corporation
Phase 1 Recruiting
Inimmune Corporation
MediLink Therapeutics (Suzhou) Co., Ltd.
Affimed GmbH
Xilio Development, Inc.
Dracen Pharmaceuticals, Inc.
Beijing Friendship Hospital